TRCT
ROIV icon

Tower Research Capital (TRC)’s Roivant Sciences ROIV Stock Holding History

Tower Research Capital (TRC)’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.16M Buy
32,746
+14,296
+77% +$422K 0.03% 559
2026
Q1 		$511K Buy
18,450
+6,968
+61% +$179K 0.01% 904
2025
Q4 		$249K Sell
11,482
-23,015
-67% -$454K 0.01% 1268
2025
Q3 		$522K Buy
34,497
+12,373
+56% +$153K 0.01% 828
2025
Q2 		$249K Sell
22,124
-7,610
-26% -$82.5K 0.01% 1586
2025
Q1 		$300K Sell
29,734
-33,724
-53% -$365K 0.01% 1141
2024
Q4 		$751K Buy
63,458
+56,534
+816% +$668K 0.01% 803
2024
Q3 		$79.9K Sell
6,924
-3,454
-33% -$39.3K ﹤0.01% 2412
2024
Q2 		$110K Sell
10,378
-252,670
-96% -$2.77M ﹤0.01% 2520
2024
Q1 		$2.77M Buy
263,048
+253,377
+2,620% +$2.73M 0.07% 209
2023
Q4 		$109K Sell
9,671
-2,660
-22% -$25.9K ﹤0.01% 2589
2023
Q3 		$144K Buy
12,331
+962
+8% +$10.9K ﹤0.01% 1695
2023
Q2 		$115K Sell
11,369
-3,306
-23% -$29.6K ﹤0.01% 1939
2023
Q1 		$108K Buy
14,675
+12,353
+532% +$102K ﹤0.01% 1805
2022
Q4 		$18K Sell
2,322
-3,054
-57% -$17K ﹤0.01% 3231
2022
Q3 		$17K Sell
5,376
-18,123
-77% -$70.2K ﹤0.01% 4080
2022
Q2 		$95K Buy
23,499
+17,737
+308% +$70.4K ﹤0.01% 2338
2022
Q1 		$28K Buy
5,762
+5,114
+789% +$33.7K ﹤0.01% 3229
2021
Q4 		$7K Buy
+648
New +$5.39K ﹤0.01% 4935

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Tower Research Capital (TRC)'s ROIV Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Roivant Sciences (ROIV) stake by 77% in Q2 2026, buying an estimated $422K and bringing the position to 32,746 shares worth $1.16M. The position accounts for 0.03% of the portfolio, ranked #559.

Tower Research Capital (TRC) first reported a position in ROIV in Q4 2021 and has held it in 19 quarters since. The position peaked at $2.77M in Q1 2024. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Tower Research Capital (TRC) held 32,746 shares of Roivant Sciences worth $1.16M as of Q2 2026.
  • Tower Research Capital (TRC) bought 14,296 Roivant Sciences shares in Q2 2026, an estimated $422K.
  • Roivant Sciences made up 0.03% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #559 holding.
  • Tower Research Capital (TRC) first reported a position in Roivant Sciences in Q4 2021 and has held it in 19 quarters since.
  • Tower Research Capital (TRC)'s Roivant Sciences position peaked at $2.77M in Q1 2024.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.